FTH (Faeth Therapeutics) Beginning Cash Position: $8.67 Mil (As of Mar. 2026)


FTH Faeth Therapeutics Inc FTH
21 GF Score
Price $24.96
! 2 Warning Signs
View Full Analysis

What is Faeth Therapeutics Beginning Cash Position?

Faeth Therapeutics FTH +0.70% 21 Beginning Cash Position is $8.67 Mil as of Mar. 2026. GuruFocus rates FTH with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

Faeth Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was $8.67 Mil.

Faeth Therapeutics's quarterly Beginning Cash Position declined from Sep. 2025 ($12.56 Mil) to Dec. 2025 ($10.56 Mil) and declined from Dec. 2025 ($10.56 Mil) to Mar. 2026 ($8.67 Mil).

Faeth Therapeutics's annual Beginning Cash Position declined from Dec. 2023 ($17.80 Mil) to Dec. 2024 ($13.01 Mil) and declined from Dec. 2024 ($13.01 Mil) to Dec. 2025 ($9.99 Mil).

Faeth Therapeutics Beginning Cash Position Related Terms

Faeth Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Faeth Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Faeth Therapeutics Beginning Cash Position Chart

Faeth Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 16.60 7.16 17.80 13.01 9.99

Faeth Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.99 9.88 12.56 10.56 8.67
FTH
21GF Score
Faeth Therapeutics Inc FTH
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Faeth Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $8.67 Mil mean?
Faeth Therapeutics (FTH) has a Beginning Cash Position of $8.67 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Faeth Therapeutics and its competitors.
Is Faeth Therapeutics' Beginning Cash Position too high?
Faeth Therapeutics' current Beginning Cash Position is $8.67 Mil. Overall, Faeth Therapeutics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Faeth Therapeutics' Beginning Cash Position compare to NEUP and KYNB?
Faeth Therapeutics' Beginning Cash Position of $8.67 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Faeth Therapeutics and its competitors. Faeth Therapeutics's current Beginning Cash Position is $8.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faeth Therapeutics stock overvalued right now?
Faeth Therapeutics (FTH) has a current Beginning Cash Position of $8.67 Mil. The current Beginning Cash Position is $8.67 Mil. Faeth Therapeutics' overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Faeth Therapeutics (FTH), the current Beginning Cash Position is $8.67 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Faeth Therapeutics Business Description

Address 701 Tillery Street No. 12, No.1010, Austin, TX, USA, 78702
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
21GF Score

Get the complete analysis for FTH

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.96
Price